By Gabriel Paijo 
In a landmark study that could redefine the early diagnosis of neurodegenerative disorders, researchers from Nanyang Technological University, Singapore (NTU Singapore) have discovered that the brain’s waste removal system frequently becomes obstructed in individuals exhibiting the earliest signs of Alzheimer’s disease. These blockages, characterized by enlarged perivascular spaces (EPVS), interfere with the brain’s critical ability to flush out metabolic toxins and appear to manifest significantly before the onset of clinical dementia symptoms. The findings suggest that these "clogged drains" could serve as a vital, non-invasive early warning signal, detectable through routine medical imaging, potentially offering a window for intervention years before irreversible brain damage occurs.
The study, led by the Lee Kong Chian School of Medicine (LKCMedicine) at NTU, highlights the clinical significance of perivascular spaces—small, fluid-filled channels surrounding the brain’s blood vessels. When these spaces become visible and enlarged on magnetic resonance imaging (MRI) scans, they indicate a failure in the glymphatic system, the body’s mechanism for clearing waste from the central nervous system. By identifying these anomalies during standard neurological evaluations, clinicians may soon be able to diagnose Alzheimer’s risk with greater precision and lower costs than currently available specialized tests.
The Biological Mechanism of Brain Clearance
To understand the significance of the NTU discovery, one must examine the role of the brain’s waste-clearance infrastructure. The human brain is an incredibly active organ, consuming a disproportionate amount of the body’s energy and, consequently, producing significant metabolic waste. Among the most dangerous of these waste products are beta-amyloid and tau proteins. In a healthy brain, these proteins are swept away through perivascular spaces into the cerebrospinal fluid and eventually out of the body.
However, as the brain ages or undergoes pathological changes, these drainage channels can become "clogged." When this happens, the perivascular spaces dilate and expand, making them visible as small dots or lines on MRI scans. For years, these enlarged spaces were often dismissed by radiologists as incidental findings associated with normal aging or small vessel disease. The NTU research clarifies that these markers are not merely signs of aging but are intrinsically linked to the biological hallmarks of Alzheimer’s disease.
"Since these brain anomalies can be visually identified on routine magnetic resonance imaging (MRI) scans performed to evaluate cognitive decline, identifying them could complement existing methods to detect Alzheimer’s earlier, without having to do and pay for additional tests," said Associate Professor Nagaendran Kandiah, the study’s lead author and Director of the Dementia Research Centre (Singapore) at LKCMedicine.
Addressing the Data Gap in Asian Populations
A pivotal aspect of this research is its focus on Asian demographics. Historically, the vast majority of Alzheimer’s clinical trials and longitudinal studies have been conducted on Caucasian populations in North America and Europe. This geographic bias has created a significant gap in medical understanding, as genetic and environmental factors vary across different ethnic groups.
Dementia does not affect all populations uniformly. For instance, the apolipoprotein E4 (APOE4) gene is widely recognized as the strongest genetic risk factor for late-onset Alzheimer’s in Western populations, with a prevalence of 50 to 60 percent among Caucasian patients. However, among Singaporean dementia patients, the prevalence of APOE4 is less than 20 percent. This discrepancy suggests that other factors, such as small vessel disease and vascular health, may play a more prominent role in the development of Alzheimer’s in Asian communities.
The NTU team addressed this disparity by examining a diverse cohort of nearly 1,000 Singaporeans, reflecting the nation’s multi-ethnic makeup of Chinese, Malay, and Indian backgrounds. The participants ranged from those with healthy cognitive function to individuals experiencing Mild Cognitive Impairment (MCI)—a transitional stage between normal aging and dementia.
Methodology: Linking Neuroimaging with Blood Biomarkers
The study’s strength lies in its multi-modal approach, combining high-resolution MRI analysis with advanced blood-based biomarker testing. The researchers measured seven specific biochemicals associated with Alzheimer’s, including various forms of beta-amyloid and phosphorylated tau (p-tau). These proteins are known to form the plaques and tangles that characterize the Alzheimer’s brain.
By comparing MRI data with blood chemistry, the scientists found that the presence of enlarged perivascular spaces was significantly correlated with four of the seven Alzheimer’s biomarkers. Specifically, individuals with "clogged" brain drains showed higher levels of amyloid-beta and tau proteins in their blood, suggesting that the failure of the brain’s clearance system is directly tied to the accumulation of toxic proteins.
Furthermore, the study compared EPVS against white matter hyperintensities—damage to the brain’s "wiring" or white matter, which is a traditional marker for vascular dementia. While white matter damage is a common clinical observation, the researchers found that in patients with early cognitive decline, the link between Alzheimer’s biomarkers and enlarged perivascular spaces was actually stronger than the link with white matter damage. This positions EPVS as a potentially more sensitive and earlier indicator of Alzheimer’s pathology than existing markers.
Chronology of the Research and Clinical Implications
The research was conducted as part of the Scholarly Project module within the Bachelor of Medicine and Bachelor of Surgery (MBBS) programme at LKCMedicine. Justin Ong, a fifth-year medical student and the study’s first author, emphasized the urgency of early detection. "Identifying Alzheimer’s sooner gives doctors more time to intervene and potentially slow the progression of symptoms such as memory loss, reduced thinking speed, and mood changes," Ong noted.
The timeline for Alzheimer’s progression is often measured in decades. Pathological changes in the brain typically begin 15 to 20 years before the first memory lapse is noticed. By the time a patient is diagnosed with dementia, significant neuronal loss has already occurred. The ability to flag high-risk individuals via a "routine" MRI scan could shift the medical paradigm from reactive care to proactive prevention.
If a patient presents with mild forgetfulness, a neurologist currently faces a complex diagnostic path. They might order an amyloid PET scan or a lumbar puncture to check for protein levels—both of which are expensive, invasive, and not always available in primary care settings. The NTU study suggests that if an MRI already shows enlarged perivascular spaces, it provides immediate clinical evidence to justify more intensive follow-up or early lifestyle interventions.
Reactions from the Medical Community
The study has garnered significant attention from clinical experts in Singapore. Dr. Rachel Cheong Chin Yee, a Senior Consultant at Khoo Teck Puat Hospital’s Department of Geriatric Medicine, noted the significance of these findings for preventative geriatrics. "These findings are significant because they suggest that brain scans showing enlarged perivascular spaces could potentially help identify people at higher risk of Alzheimer’s disease, even before symptoms appear," said Dr. Cheong, who was not involved in the research.
Similarly, Dr. Chong Yao Feng, a Consultant at the National University Hospital’s Division of Neurology, highlighted how the study challenges the traditional separation of vascular and neurodegenerative diseases. "The study’s findings are intriguing as they demonstrate that both diseases do interact in a synergistic manner," Dr. Chong remarked. He advised that clinicians should be cautious not to attribute cognitive symptoms solely to vascular issues when EPVS are present, as they likely signal a concurrent Alzheimer’s risk.
Broader Impact and Future Directions
The implications of this research extend beyond the laboratory. As global populations age, the economic and social burden of dementia is projected to skyrocket. Early diagnosis is widely considered the "Holy Grail" of Alzheimer’s research because it allows for the testing of new disease-modifying therapies at a stage when the brain is still largely intact.
For the NTU team, the next phase involves a longitudinal study. They plan to track their 1,000-person cohort over several years to see how many of those with enlarged perivascular spaces eventually progress to a clinical diagnosis of Alzheimer’s. This will provide the definitive evidence needed to turn EPVS into a standardized diagnostic criterion.
Furthermore, this research paves the way for a more personalized approach to brain health. If the brain’s waste removal system is the primary point of failure, treatments could focus on "unclogging" these pathways. Emerging research into sleep quality, hydration, and cardiovascular exercise suggests these factors can improve glymphatic clearance, offering a non-pharmacological route to slowing cognitive decline.
In conclusion, the discovery by NTU Singapore scientists provides a critical piece of the Alzheimer’s puzzle. By identifying a visible, physical marker of the brain’s failing waste system, they have provided a new tool for clinicians to fight a disease that has long remained elusive. As medical science moves toward earlier detection and more targeted therapies, the ability to see the "clogged drains" of the brain may become one of the most important steps in preserving cognitive health for the world’s aging population.